VEGFA and cancer: Finally, several cancer therapies have been recognized to cause QTc prolongation, including arsenic trioxide, HDAC inhibitors, tyrosine kinase inhibitors (e.g., vandetanib, vemurafenib, ceritinib, gilteritinib, trametinib, and those targeting BCR-Abl and the VEGF signaling pathway), and Cyclin-dependent kinase (CDK) 4–6 inhibitors [4].